Yervoy is an intravenous injection first approved in 2011 to treat adults with metastatic melanoma. The drug may now be used to treat patients 12 years and older with unresectable or metastatic melanoma.
The approval marks Bristol Myers’ first pediatric indication for an immunotherapy drug.
More articles on supply chain:
Supply chain leaders worried about potential market entry of Amazon
Drug prices will jump nearly 8% for health systems in 2018: 3 report findings
10 most popular prescription drugs for 2017
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
